Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

This is the logo of the provider
International Society on Thrombosis and Haemostasis - 34th Congress, 2026 (ISTH) 11 - 15 July 2026

Concizumab prophylaxis in paediatric participants with haemophilia A/B with inhibitors in the phase 3 explorer10 study: Efficacy, safety and PK/PD results from the 32-week cut-off

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Rare Blood Disorders
Congress oral presentation
Concizumab